Introduction
Many receptor tyrosine kinases and cytokine receptors in association with heterotrimeric G proteins are known to activate intracellular protein serine/threonine kinases termed mitogen-activated protein kinases (MAPKs). Of the various families of MAPKs, which are also referred to as extracellular signal-regulated kinases (ERKs), the ®rst to be characterized were ERK1 and ERK2. Both of these ERKs are activated in response to diverse extracellular stimuli and by protooncogene-encoded proteins that induce proliferation. A cascade of phosphorylation events downstream from Ras activates these kinases. Upstream regulation of the MAP kinase pathway is complex as evidenced by the number of functions ful®lled by its activation. Processes impacted by MAPK activation encompass the cytoplasm, nucleus, cytoskeleton, and the membrane. The reader is referred elsewhere for comprehensive reviews on the subject of regulation through MAPK cascades (Cobb, 1999; Lewis et al, 1998; Kolch, 2000) .
The Raf-MEK-ERK pathway represents one of the best characterized Ras signaling pathways. Raf and MEK have consequently emerged as key protein kinases to target for anticancer drug design. While there exist multiple MAP kinase families, e.g. jun kinase and p38, which are also activated downstream of low molecular weight G-proteins, ERK has been the best characterized and is more pertinent to aberrant signaling in human cancer. For some cancers, especially those of hematopoietic origin, the p38 and jun kinase pathways may in fact yield targets exploitable for anticancer drug development. However, a broad array of solid tumors is known to express constitutive levels of phosphorylated ERK1 and ERK2. Activation of ERK is critical for a large number of Ras-induced cellular responses. Included among these responses is transcriptional activation of multiple genes (Hill and Treisman, 1995) . The best-characterized physiological substrates of ERK are ternary complex factors (TCFs), which are directly phosphorylated by ERK to activate their transcription activation potential (Gille et al., 1992; Janknect et al., 1993; Marais et al., 1993) . TCFs, in association with serum response factor, is thought to be critical for the activation of numerous mitogeninducible genes (Hill and Treisman, 1995) .
Many molecules ultimately contribute to activation of the Ras-ERK pathway, including a number that are involved in protein-protein interactions. With respect to pharmacological intervention, it is generally dicult to selectively target the binding site shared by two proteins. It is therefore not coincidental that the development of agents targeting the Ras-MAPK pathway has largely focused on the design of small molecule inhibitors of enzyme function. As will be explored in more detail below, four proteins have emerged as key players in the quest to intervene in this pathway: Ras, Raf, MEK (MAP kinase kinase), and ERK. Ras is the subject of a paper that appears elsewhere in this review issue and therefore will not be covered further here.
Rationale for targeting the MAP kinase pathway
Figure 1 provides a simpli®ed schematic representation of the signaling events leading to activation of the MAP kinase pathway. Initially, Ras interacts with and activates the serine/threonine protein kinase Raf1 in a GTP-dependent manner (Daum et al., 1994; Stokoe et al., 1994) . A family of Raf protein kinases has been identi®ed and is comprised of A-Raf, B-Raf, and cRaf1. It has been suggested that this family of kinases, which is known to regulate proliferation, dierentiation, and apoptosis, have both overlapping and unique regulatory functions (Hagemann and Rapp, 1999) . For example, transfection of oncogenic H-ras led to a preferential activation of endogenous c-Raf1 as opposed to A-Raf (Weber et al., 2000) . Mutated Raf-1 is constitutively active and possesses in vitro transforming potential (Stanton and Cooper, 1987) . The potential for Raf-1 to play a broad role in tumorigenesis is evidenced by its ability to become activated by either PKCa or the antiapoptotic protein Bcl-2 in a Ras-independent manner (Kolch et al., 1993; Wang et al., 1996) . Importantly, raf mutations have been identi®ed in a range of human tumors (Storm and Rapp, 1993) . Independent of its mutation status, Raf is also activated in tumor cells containing enhanced growth factor signaling pathways, such as those induced by mutant or constitutively expressed Ras or EGF receptor family members. Therefore, the collective evidence suggests that Raf-1 is a viable anticancer drug target.
Alternatively, targeting the molecule immediately downstream from Raf, that is, the dual speci®city kinase MEK can also be envisioned as representing a rational approach to anticancer drug design. Subsequent to its activation, Raf-1 phosphorylates and activates both MEK1 and MEK2 (hereafter referred to as MEK) on two distinct serine residues (Dent et al., 1992; Crews et al., 1992; Her et al., 1993) . Activated MEK then phosphorylates ERK1 and ERK2 on both a tyrosine and a threonine residue (Anderson et al., 1990) . No substrates for MEK have been identi®ed other than ERK1 and ERK2 (Seger et al., 1992) . This tight selectivity in addition to the unique ability to phosphorylate both tyrosine and threonine residues are consistent with this kinase playing a central role in integration of signals into the MAPK pathway. Constitutive activation of MEK has been shown to result in cellular transformation (Cowley et al., 1994; Mansour et al., 1994) . While MEK has not been identi®ed as an oncogene product, MEK is the focal point of many signal transduction mitogenic pathways activated by proven oncogenes. Pivotal studies carried out with the MEK inhibitor PD98059 provided further impetus for exploring whether MEK could be exploited as a target for rational anticancer drug design. In these studies, MEK inhibition not only impaired proliferation, but also impacted a diverse array of cellular events, including dierentiation, apoptosis, and angiogenesis Alessi et al., 1995; Pages et al., 1993; Pang et al., 1995; Finlay et al., 2000; Holmstrom et al., 1999; Elliceiri et al., 1998; Milanini et al., 1998) . Based on these collective ®ndings, MEK therefore represents an attractive target for pharmacological intervention in cancer.
Theoretically, it could be argued that intervention in any of the kinase events in the MAPK cascade could represent a viable approach to crippling tumor growth. If so, then Raf-1, MEK, and ERK all emerge as reasonable anticancer drug targets. The advent of high volume screening of pharmaceutical libraries for small molecule inhibitors has most certainly produced reasonable drug candidates targeting all steps of this pathway. For example, a cascade assay has been reported that is capable of identifying inhibitors of cRaf1, MEK1, or ERK2 (McDonald et al, 1999) . As we now turn to preclinical and clinical evaluation of these small molecule inhibitors, it is important to keep in mind that their ultimate promise or dierences may depend as much on their pharmacological attributes as on the merits of their targeted kinase.
It should be noted that the identi®cation of pathway components in the Ras-MAP kinase pathway is likely incomplete. For example, a Raf-1-interacting protein, RKIP, has recently been reported (Yeung et al., 1999) . This protein inhibits the phosphorylation and activation of MEK by Raf-1 and has also been shown to co-localize with Raf-1. It has been proposed that RKIP binding to either Raf-1 or MEK dissociates Raf-MEK complexes, thereby interrupting MEK activation and downstream signaling (Yeung et al., 2000) . Discovered with the use of a yeast two-hybrid system, the relevance of RKIP expression to signal transduction in tumor cells is unclear at the present time. Furthermore, until we learn whether RKIP expression is negatively regulated, it remains unclear how to pharmacologically elevate its expression to impair tumor growth. Although highly speculative based on our current knowledge of the role of RKIP, it is conceivable that elevated expression of this protein could oer tumor cells a mechanism of resistance to MAPK pathway inhibitors.
There exist a multitude of other newly discovered proteins that may provide insight into the design of novel signal transduction-based cancer therapies that exploit the MAP kinase pathway. These include Sur-8, which is thought to act as a scaold to enhance Ras-MAP kinase signaling by facilitating Ras-Raf interaction (Li et al., 2000) , as well as the kinase suppressor of Ras (KSR). KSR is also thought to act as a scaolding protein for the Ras-MAPK pathway (Stewart et al., 1999) . Another interesting protein is MP-1, which has been reported to enhance activation of the MAPK by binding MEK (Schaeer et al., 1998) . Last but not least, a novel ERK has recently been identi®ed, ERK1b, which is an alternatively spliced form of ERK1, that appears to be elevated in Ras-transformed cells (Yung et al., 2000) .
Amenability of the MAP kinase pathway to pharmacodynamic evaluation
Using an antibody speci®c for dually phosphorylated ERK1 and ERK2, in vivo evaluation of MEK inhibition can easily be measured in excised samples. The utility of such an assay in preclinical animal models was demonstrated for the MEK inhibitor PD184352 (Sebolt-Leopold et al., 1999) . Phosphorylated MAPK is the product of MEK activity and thus represents a direct measure of MEK inhibition. Using an antibody speci®c for phosphorylated MEK, ex vivo evaluation for Raf inhibition should likewise be straightforward. However, pharmacodynamic evalua- At the preclinical stage, pharmacodynamic assays are not only useful for optimizing the design of dosing regimens, but also oer the advantage of being able to correlate antitumor ecacy with inhibition of the biochemical target. A large number of cell lines as well as primary human tumors have been surveyed for constitutive activation of the MAPK pathway (Hoshino et al., 1999) . It will be of interest to correlate the degree of target expression of a given tumor with its inherent sensitivity to agents directed against that target. The data obtained thus far with the MEK inhibitor PD184352 suggest that tumors containing high level expression of phosphorylated MAP kinase are most sensitive to treatment with this agent (Sebolt-Leopold et al., 1999) . There are obvious clinical implications if this pattern continues during the expansion of our database; such assays could then be exploited as prognostic tools to identify those patients most likely to derive therapeutic bene®t from treatment with a given agent. Figure 2 demonstrates the applicability of pharmacodyamic evaluation of PD184352 to a range of tissues or cells (Sebolt-Leopold, unpublished data). Twentyfour hours after an oral dose of 200 mg/kg was administered to monkeys, signi®cant inhibition of MAPK phosphorylation was observed in lung as well as skin tissue (Figure 2a,b, respectively) . Looking ahead to the clinical setting, biomarker evaluation of phosphorylated MAPK levels can also be measured in PMA-stimulated peripheral blood mononuclear cells (Figure 2c ). Such assays have the potential to de®ne a dose threshold that delivers total suppression of the desired target. For a target such as MEK that is thought to oer tumor-speci®c pharmacologic eects, Phase II trials may not need to be carried out at the MTD determined from Phase I studies.
Pharmacological approaches to targeting the MAPK pathway
The only Raf-directed approach for which preclinical ecacy data have been published is that employing a craf-1 antisense oligonucleotide. ISIS 5132 is a 20-base phosphorothioate antisense oligodeoxynucleotide designed to hybridize to 3' untranslated sequences of craf-1 mRNA (Monia et al., 1996) . Reduction of c-raf-1 mRNA was shown to occur in tumor-bearing mice treated with relatively low doses. Importantly, preclinical ecacy and toxicology studies suggested a large therapeutic window for ISIS 5132 (Henry et al., 1997) . Early clinical data have recently been reported with ISIS 5132 Yuen and Sikic, 2000) . This agent was well tolerated and suppression of target gene expression was observed in peripheral blood mononuclear cells . However, Phase II data have not yet been published.
It is anticipated that clinical data will soon emerge from testing of small molecule inhibitors of raf kinase. Based on the patent literature, several classes of substituted ureas have been identi®ed as raf kinase inhibitors (Bayer, 1999a (Bayer, ,b,c, 2000 . Benzamides have also been investigated for their raf kinase inhibitory activity (Zeneca, 1998) . It has been reported that a potent and speci®c inhibitor of Raf isoforms in vitro, ZM 336372 paradoxically induces signi®cant activation of c-Raf without inducing any activation of MEK1 or ERK2 (Hall-Jackson et al., 1999) . The authors speculate that Raf may suppress its own activation by virtue of a novel feedback loop. If so, then inhibition would be counterbalanced by reactivation which would limit the utility of raf kinase inhibitors as anticancer agents. Clinical testing of raf kinase inhibitors will likely clarify this paradox. It should also be noted that growth factor-stimulated ERK is capable of retrophosphorylating MEK in a negative feedback fashion (Brunet et al., 1994 ). Yet, MEK inhibitors, e.g. PD184352, clearly exhibit promising preclinical activity in a number of human and murine tumor models. This suggests that the retrophosphorylation-derived negative regulation does not inactivate the pathway.
An orally active small molecule inhibitor of MEK has provided in vivo validation for targeting MEK for anticancer drug design (Sebolt-Leopold et al., 1999) . In this study, PD184352, a non-ATP-competitive, highly selective inhibitor of MEK, was found to signi®cantly inhibit growth of colon carcinomas of both mouse and human origin. Importantly, ecacy was achieved at well tolerated doses and was correlated with a reduction in the levels of activated MAPK in excised tumors. In addition to impairing tumor proliferation, PD184352 was found to block the disruption of cellcell contact and motility required for invasion. This ®nding is consistent with earlier reports indicating that hepatocyte growth factor (HGF) induces dispersion of epithelial cells by a Ras-dependent mechanism. The MEK/MAPK pathway is an essential mediator of HGF-induced cell scattering (Ridley et al., 1995; Herrera, 1998; Potempa and Ridley, 1998; Tanimura et al., 1998) . PD184352 (now designated CI-1040) is presently undergoing Phase 1 evaluation in cancer patients.
Once activated, a fraction of cytoplasmic ERK1 and ERK2 translocates into nuclei (Lenormand et al, 1993) . In this way, these MAP kinases enable the regulation of gene expression by phosphorylation of nuclear transcription factors. While selective ERK1/ERK2 inhibitors have not been described in the literature, Figure 2 Eects of the MEK inhibitor PD184352 on phosphorylated MAP kinase (pMAPK) levels in (a) monkey lung, (b) monkey skin, and (c) human peripheral blood mononuclear cells (PBMCs). Monkeys were administered an oral dose of 200 mg/mg PD184352 (+) or diluent (7) followed 24 h later by excision of the indicated tissue for analysis of pMAPK. Human whole blood was spiked with 1 mM PD184352 followed immediately by stimulation with PMA and isolation of PBMCs for evaluation of pMAPK levels intervention in activation of transcription factors may prove to be an exploitable approach for anticancer drug development. Until ERK inhibitors are evaluated, the pharmaceutical attractiveness of this kinase is left to speculation. It is not clear whether direct inhibition of ERK would prove to be more toxic than inhibition of the upstream kinases Raf and MEK. Whereas a null mutation in the MEK1 gene proved to be embryonic lethal, ERK1 knockout mice were viable and of normal size (Giroux et al., 1999; Pages et al 1999) . However, in the case of the p38 MAP kinase family, it has been shown that p38 null mutants result in an embryonic lethal phenotype, unlike the case for MKK3 knockouts (Allen et al., 2000; Lu et al., 1999) . Aside from unresolved theoretical concerns regarding potential toxicities, a priori ERK and MEK inhibitors might be expected to act similarly since ERK can only be activated by MEK. This is in contrast to the situation in the p38 pathway where p38 can be activated by three distinct MKKs. Therefore, to target the pertinent upstream MAP kinase kinases in the p38 pathway, it might prove necessary to abolish activity of not one but three enzymes, namely MKK3, MKK4, and MKK6.
Blockade of the MAP kinase pathway exerts pleiotropic effects exploitable in future clinical trial design
Of the numerous therapeutic approaches to cancer treatment, most take the form of a single-pronged attack aimed at either: (1) slowing of tumor growth, (2) inhibition of invasion and metastasis, (3) induction of tumor cell death, or (4) promotion of tumor dierentiation. However, by pharmacological intervention of the MAP kinase pathway, one can envision a single agent that concurrently exploits more than one of these processes. Perhaps the best evidence in support of this statement is provided by the collective data obtained with MEK inhibitors.
Greater than 1500 references appear in the literature describing the utility of PD98059 in elucidating the role of the MAP kinase pathway in diverse cellular processes. The involvement of this pathway in tumor proliferation is well documented. While not all tumors rely on MAP kinase activation to drive their growth, a signi®cant percentage of human tumors do in fact exhibit constitutive activation of the MAPK pathway (Hoshino et al., 1999) . MEK inhibition has been shown to eectively shut down tumor growth in vivo in a cytostatic manner (Sebolt-Leopold et al., 1999) . However, MEK inhibition has also proven to induce tumor regressions in some xenograft models, e.g. pancreatic BxPc3, as exempli®ed in Figure 3 (Merriman and Sebolt-Leopold, unpublished data). These results are consistent with an increase in apoptosis occurring in response to MEK inhibition. This is perhaps not surprising in view of evidence that one of the phosphorylation sites on the pro-apoptotic molecule BAD, i.e. serine-112, is phosphorylated by MAP kinase (Fang et al., 1999; Scheid et al., 1999) . Phosphorylation of this site results in loss of the ability of BAD to heterodimerize with the survival protein BCL-2. Thus, by promoting interaction between BAD and BCL-2, it appears feasible that inhibition of MEK would serve to increase the incidence of apoptosis. In BxPc3 tumors that had regressed in response to treatment with the MEK inhibitor CI-1040, reduced phosphorylation of the serine-112 site on BAD was demonstrated ex vivo (Sebolt-Leopold, unpublished results). It should also be noted that a recent report indicates that activation of the MAPK pathway acts to protect pancreatic tumor cells from apoptosis by regulating expression of Bcl-2 (Boucher et al., 2000) .
Inhibition of MAP kinase signaling is also anticipated to result in anti-metastatic and anti-angiogenic eects. Activation of the MAPK pathway occurs in response to integrin-mediated cellular adhesion to the extracellular matrix, which plays a critical role in both tumor metastasis and angiogenesis (Chen et al., 1994; Zhu and Assoian, 1995) . It was recently reported that active ERK is targeted to newly formed focal adhesions after integrin engagement of v-Src activation, providing support for a role for ERK in regulation of adhesion (Fincham et al., 2000) . Transfection of constitutively active MEK, which resulted in increased expression of matrix metalloproteinases 2 and 9 as well as cathepsin L, resulted in macroscopic metastases (Welch et al., 2000) . It is therefore not surprising that MEK inhibition in colon tumor models resulted in decreased invasiveness as well as inhibition of cell motility (Sebolt-Leopold et al., 1999) . It is also anticipated that inhibition of MAPK signaling will negatively impact angiogenesis. Such an eect is likely based on our knowledge of sustained activation of MAPK being required for angiogenesis (Eliceiri et al., 1998) . MAPK activation is probably also required for growth factor-induced secretion of angiogenic growth factors from tumor cells (Petit et al., 1997) .
Therefore, evidence would seem to suggest that single agent treatment with a drug targeted against the MAPK pathway could potentially impair tumor survival by more than one of the therapeutic approaches outlined above. It is likely however that the design of future clinical trials with MAPK pathway inhibitors will attempt to boost therapeutic kill by employing combination regimens. Two classes of chemotherapeutic agents of particular interest in this regard are mitotic inhibitors, e.g. taxanes, as well as platinum-coordination complexes, e.g. cisplatin and carboplatin. The kinetochore motor protein CENP-E, which was found in vivo to associate preferentially with active MAPK during mitosis, was also phosphorylated by MAPK at sites known to regulate its interactions with microtubules (Zecevic et al., 1998) . These investigators propose that MAP kinase may play a role in mitosis by aecting the ability of CENP-E to mediate interactions between microtubules and chromosomes. Cell culture experiments have shown that the combination of taxol with the MEK inhibitor CI-1040 results in a signi®cant increase in apoptotic frequency that is greater than that predicted from the additive eects of each agent tested alone (Sebolt-Leopold, unpublished data).
With respect to platinum coordination complexes, cisplatin treatment of ovarian carcinoma cells or HeLa cells has been reported to result in induction of ERK activity (Persons et al., 1999; Wang et al., 2000) . Furthermore, inhibition of cisplatin-induced ERK activity by the MEK inhibitor PD98059 resulted in enhanced cytotoxicity in response to cisplatin treatment. Thus the combination of cisplatin or carboplatin with MAPK pathway inhibitors warrants further investigation for potential clinical bene®t. The p53 phenotype may play a role in determining whether the combination of a MAPK signaling antagonist with a cytotoxic agent results in synergistic cell kill, since a link has been established between p53 signaling and the MAPK cascade. It has been reported that treatment of normal cells with DNA-damaging agents induced ERK activation in a p53-dependent manner, whereas tumorderived p53 mutants that were defective in DNAbinding failed to activate ERK (Lee et al., 2000) . Interestingly, it was recently reported that inhibition of ERK activation by MEK inhibition resulted in decreased accumulation of p53 during exposure to cisplatin (Persons et al., 2000) . These investigators further showed that p53 was phosphorylated by ERK in vitro in an event antagonized by MEK inhibition during cisplatin treatment. Thus it appears likely that ERK activation induced by cisplatin regulates the p53 response to cytotoxic damage induced by this DNAdamaging agent.
While only two examples have been given here, one could rationalize the combination of a MAPK pathway inhibitor with a multitude of other agents. If single agent treatment with MAPK signaling antagonists proves to be well tolerated upon chronic dosing, it is tempting to speculate that these drugs might also prove useful in preventing the emergence of hormoneresistant cancers. For example, estrogen-dependent breast cancers that initially respond to tamoxifen treatment frequently become resistant. It has been shown that this shift in hormone-response pattern is accompanied by a shift from MAPK-independent to MAPK-dependent cell growth (Lange et al., 1996) . Along these same lines, data exist in support of increased activation of the MAP kinase pathway as prostate cancer progresses to a more advanced and androgen-independent state (Gioeli et al., 1999) .
Looking to the future
The ultimate therapeutic promise of signaling antagonists directed against the MAPK pathway can only be determined from human testing. Until we have gained clinical experience on their safety and ecacy pro®les, arguing the merits of targeting one kinase versus another remains an academic exercise. Clearly, the chances for clinical success will be enhanced if human trials are designed to exploit the mechanism of action of the agent under study. Combination regimens employing chemotherapeutic agents have generally been driven by safety considerations, i.e. combination of cytotoxic agents with non-overlapping toxicities. With the development of signaling antagonists that are considerably less toxic, it will be important to turn our attention to combining MAPK pathway inhibitors with cytotoxic agents or with other signaling antagonists based on anticipated mechanistic-based synergy.
As these agents enter the clinic, reagents will be available to directly monitor target suppression. The use of such biomarker analysis will not only aid dose escalation, but also oers the advantage of correlating ecacy with the degree of activity anticipated by the extent of target suppression. The advantages of having pharmacodynamic assays available for analysis of clinical samples can not be overstated. The ®eld of clinical oncology is plagued by examples of negative clinical trials, where it is not clear if lack of ecacy was due to the inhibited target being inconsequential to outcome or simply whether the requisite degree of target inhibition was not achieved. Furthermore, if retrospective data analysis from clinical trials shows that the degree of target expression correlates well with sensitivity to the test agent, then this has obvious prognostic implications when tumor biopsy material is available.
In summary, the next decade will no doubt represent a very exciting time in the ®eld of clinical oncology, as a number of signaling antagonists, including inhibitors of the MAP kinase pathway, get put to the real test.
